NCT04150341 - Effect of Inhaled TD-8236 on Allergen-induced Asthmatic Response | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 6, 2019

Primary Completion Date

August 28, 2020

Study Completion Date

September 3, 2020

Conditions

Asthma

Interventions

DRUG

TD-8236

The study drug will be administered by inhalation in the morning for 14 days during each period. A washout period of at least 21 days will exist between subsequent periods.

DRUG

Placebo

The placebo will be administered by inhalation in the morning for 14 days during each period. A washout period of at least 21 days will exist between subsequent periods.

Trial Locations (2)

W1G 8HU

Theravance Biopharma Investigational Site, London

M23 9QZ

Theravance Biopharma Investigational Site, Manchester